SA is one step closer to a new TB vaccine, but there is a lot of work ahead
South Africa is preparing for the potential rollout of a new tuberculosis vaccine, M72, which is currently in phase three clinical trials. Experts emphasize that successful regulatory approval must be accompanied by comprehensive logistical and manufacturing planning to effectively address the country's high TB mortality rate.
Why it matters
A successful vaccine could drastically reduce TB-related deaths in South Africa, which currently bears a significant portion of the global disease burden.
Facebook 0 Tweet 0 Email 0 In March 2024, a pivotal clinical trial was launched to evaluate what might well become the first new tuberculosis vaccine on the market in more than a century. As anticipation mounts for the trial to deliver results, Russell Rensburg argues that we need to start preparing for a rollout of the jab, but that we should think of preparation more widely than just the technicalities of regulatory approval and drug supply.
Over the past few weeks, there have been ongoing discussions about a potential new TB vaccine coming to South Africa.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in